Results 131 to 140 of about 1,087,510 (314)

Healthy Living for Elders: Are You at Risk for Drug Interactions?

, 1969
Jennifer Hillan
openalex   +2 more sources

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Interactions Between Clonidine and α-Adrenoceptor Blocking Drugs on the Tachycardic Response to Stimulation of the Cardiac Nerve in Dogs

, 1979
P Mouillé, Anne‐Marie Huchet, Bernadette Lucet, Jacques E. Chelly, Henri Schmitt   +4 more
openalex   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers

Drug Design, Development and Therapy
Qian Chen,1,2 Chengyin Yu,1,2 Qingqing Wu,1,2 Rong Song,1,2 Ye Liu,1,2 Sheng Feng,3 Chen Yu,1,2 Jingying Jia1,2 1Center Laboratory, Shanghai Xuhui Central Hospital, Shanghai, People’s Republic of China; 2Shanghai Engineering Research Center of Phase I ...
Chen Q, Yu C, Wu Q, Song R, Liu Y, Feng S, Yu C, Jia J   +7 more
doaj  

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895. [PDF]

Cancer Res Commun
Stromatt JC, Ahmed EA, Drabison T, Nepal MR, Chowdhury AT, Orwick SJ, Buelow DR, Eisenmann ED, Huang KM, Sparreboom A, Baker SD.   +10 more
europepmc   +1 more source

Transformation and Excretion of Drugs in Biological Systems. IX. Interactions between Sulfinpyrazone and Sulfonamides, and between Oxyphenbutazone and Sulfonamides in Dogs

, 1974
Masahiko Takada, Ayako Misawa, Koichi Fujimoto, Ryohei Hori, Takaichi Arita   +4 more
openalex   +2 more sources

A Manual of Adverse Drug Interactions [PDF]

, 1976
A. R. M.
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source